Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q2 2011
Executive Summary
Of the $6.3 billion total raised, 32% was from China distributor Shanghai Pharmaceuticals' $1.99 billion IPO - not only Q2's biggest financing, but also the second-largest pharma IPO of all time. Six of the 26 completed mergers were done to gain access to emerging markets, most notably, Takeda's $13.7 billion buy of Nycomed, almost half of the total $27.9 billion spent on pharma acquisitions this quarter. Q2's largest alliance was Vertex's in-licensing of Alios BioPharma's preclinical HCV nucleotide analogues, a deal that could be worth up to $775 million in up fronts and development milestones.
You may also be interested in...
Pfizer: Established Products And Consumer Health In; Animal Health And Nutrition Out
Pfizer takes a middle-of-the-road approach to breaking out non-core businesses, announcing plans to explore alternatives for Animal Health and Nutrition.
Abbott Refreshes Rheumatoid Arthritis Strategy By Licensing Biotest's Phase II Candidate
For $85 million up-front in a deal potentially worth $480 million, Abbott gets a mid-stage antibody that could be a possible successor to strong-selling Humira.
Vertex Prepares For HCV Combo Research By Licensing Two Compounds From Alios
Vertex pays $60 million upfront to license two nucleotide polymerase inhibitors it will test in combination therapy with other HCV assets in its pipeline.